Natsuhara KH, Chien AJ. Impact of systemic therapy on fertility in women with early-stage breast cancer. Curr Breast Cancer Rep. 2024;16:61–8. https://doi.org/10.1007/S12609-023-00516-Z.

Article  PubMed  PubMed Central  Google Scholar 

Bou-Dargham MJ, Draughon S, Cantrell V, Khamis ZI, Sang QXA. Advancements in human breast cancer targeted therapy and immunotherapy. J Cancer. 2021;12:6949. https://doi.org/10.7150/JCA.64205.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tauber N, Amann N, Dannehl D, Deutsch TM, Dimpfl M, Fasching P, et al. Therapy of early breast cancer: current status and perspectives. Arch Gynecol Obstet. 2025;312:311–28. https://doi.org/10.1007/S00404-025-08028-0.

Article  PubMed  PubMed Central  Google Scholar 

Vuong S, Warner E. Breast Cancer survivorship among younger patients: challenges and opportunities-narrative review. Ann Palliat Med. 2024;13:1246–57. https://doi.org/10.21037/APM-24-64.

Article  PubMed  Google Scholar 

Soldato D, Arecco L, Agostinetto E, Franzoi MA, Mariamidze E, Begijanashvili S, et al. The future of breast cancer research in the survivorship field. Oncol Ther. 2023;11:199. https://doi.org/10.1007/S40487-023-00225-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mannion S, Higgins A, Larson N, Stewart EA, Khan Z, Shenoy C, et al. Prevalence and impact of fertility concerns in young women with breast cancer. Sci Rep. 2024;14(1):4418. https://doi.org/10.1038/s41598-024-54961-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lambertini M, Peccatori FA, Demeestere I, Amant F, Wyns C, Stukenborg JB, et al. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO clinical practice guidelines. Ann Oncol. 2020;31:1664–78. https://doi.org/10.1016/j.annonc.2020.09.006.

Article  CAS  PubMed  Google Scholar 

Su HI, Lacchetti C, Letourneau J, Partridge AH, Qamar R, Quinn GP, et al. Fertility preservation in people with cancer: ASCO guideline update. J Clin Oncol. 2025;43:1488–515. https://doi.org/10.1200/JCO-24-02782.

Article  PubMed  Google Scholar 

Arecco L, Omar A, de Moura Leite L, Janković K, Gentile G, Stana M, et al. The value of offering oncofertility counseling in young patients with newly diagnosed cancer is unquestionable. JCO Oncol Pract. 2025;21:578–9. https://doi.org/10.1200/OP-24-00634.

Article  PubMed  Google Scholar 

Nabholtz JMA. Long-term safety of aromatase inhibitors in the treatment of breast cancer. Ther Clin Risk Manag. 2008;4:189–204. https://doi.org/10.2147/TCRM.S1566.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abe O, Abe R, Enomoto K, Kikuchi K, Koyama H, Masuda H, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771–84. https://doi.org/10.1016/S0140-6736(11)60993-8.

Article  CAS  Google Scholar 

Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28:509–18. https://doi.org/10.1200/JCO.2009.23.1274.

Article  CAS  PubMed  Google Scholar 

Yamazaki R, Inokuchi M, Ishikawa S, Ayabe T, Jinno H, Iizuka T, et al. Ovarian hyperstimulation closely associated with resumption of follicular growth after chemotherapy during tamoxifen treatment in premenopausal women with breast cancer: a multicenter retrospective cohort study. BMC Cancer. 2020;20:67. https://doi.org/10.1186/S12885-020-6549-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Berliere M, Duhoux FP, Dalenc F, Baurain JF, Dellevigne L, Galant C, et al. Tamoxifen and ovarian function. PLoS ONE. 2013. https://doi.org/10.1371/JOURNAL.PONE.0066616.

Ravdin PM, Fritz NF, Tormey DC, Jordan VC. Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen. Cancer Res. 1988;15:1026–9.

Google Scholar 

Jordan VC, Fritz NF, Tormey DC. Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer. Cancer Res. 1987;15:624–30.

Google Scholar 

Kim H, Han W, Ku SY, Suh CS, Kim SH, Choi YM. Feature of amenorrhea in postoperative tamoxifen users with breast cancer. J Gynecol Oncol. 2017. https://doi.org/10.3802/JGO.2017.28.E10.

Article  PubMed  PubMed Central  Google Scholar 

Jordan VC, Fritz NF, Langan-Fahey S, Thompson M, Tormey DC. Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. J Natl Cancer Inst. 1991;83:1488–91. https://doi.org/10.1093/JNCI/83.20.1488.

Article  CAS  PubMed  Google Scholar 

Silva C, Ribeiro Rama AC, Reis Soares S, Moura-Ramos M, Almeida-Santos T. Adverse reproductive health outcomes in a cohort of young women with breast cancer exposed to systemic treatments. J Ovarian Res. 2019;12:102. https://doi.org/10.1186/S13048-019-0581-6.

Article  PubMed  PubMed Central  Google Scholar 

Dezellus A, Barriere P, Campone M, Lemanski C, Vanlemmens L, Mignot L, et al. Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer. Eur J Cancer. 2017;79:72–80. https://doi.org/10.1016/j.ejca.2017.03.035.

Article  CAS  PubMed  Google Scholar 

Anderson RA, Mansi J, Coleman RE, Adamson DJA, Leonard RCF. The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer. Eur J Cancer. 2017;87:58–64. https://doi.org/10.1016/j.ejca.2017.10.001.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chien AJ, Duralde E, Hwang R, Tsung K, Kao CN, Rugo HS, et al. Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer. Breast Cancer Res Treat. 2015;153:173–81. https://doi.org/10.1007/S10549-015-3511-3.

Article  CAS  PubMed  Google Scholar 

Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, Price K, et al. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13–93. J Clin Oncol. 2006;24:1332–41. https://doi.org/10.1200/JCO.2005.03.0783.

Article  CAS  PubMed  Google Scholar 

Swain SM, Land SR, Ritter MW, Costantino JP, Cecchini RS, Mamounas EP, et al. Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial. Breast Cancer Res Treat. 2009;113:315–20. https://doi.org/10.1007/S10549-008-9937-0.

Article  CAS  PubMed  Google Scholar 

Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999;17:2365–70. https://doi.org/10.1200/JCO.1999.17.8.2365.

Article  CAS  PubMed  Google Scholar 

Zhou WB, Yin H, Liu XA, Zha XM, Chen L, Dai JC, et al. Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and Navelbine in younger breast cancer patients. BMC Cancer. 2010;10:281. https://doi.org/10.1186/1471-2407-10-281.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Y, Li Y, Liang J, Zhang N, Yang Q. Chemotherapy-induced amenorrhea and its prognostic significance in premenopausal women with breast cancer: an updated meta-analysis. Front Oncol. 2022;12:859974. https://doi.org/10.3389/FONC.2022.859974/FULL.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zavos A, Valachis A. Risk of chemotherapy-induced amenorrhea in patients with breast cancer: a systematic review and meta-analysis. Acta Oncol. 2016;55:664–70. https://doi.org/10.3109/0284186X.2016.1155738.

Article  CAS  PubMed  Google Scholar 

Poorvu PD, Hu J, Zheng Y, Gelber SI, Ruddy KJ, Tamimi RM, et al. Treatment-rela